According to the report, the global antithrombin treatment market was valued at US$ 0.50 Bn in 2022 and is anticipated to expand at a CAGR of 5.3% from 2022 to 2030.
According to the report, the global antithrombin treatment market was valued at US$ 0.50 Bn in 2022 and is anticipated to expand at a CAGR of 5.3% from 2022 to 2030
Rising Usage of Rapid Diagnostic Tests that Use Antithrombin Fuel Demand in Antithrombin Market
The rising incidence of various health conditions such as sepsis, disseminated intravascular coagulation or DIC, congenital antithrombin deficiency, and extracorporeal membrane oxygenation or ECMO is anticipated to boost the demand in the global antithrombin market in coming years. Another major driver for the global antithrombin market is the increasing demand and instances of elevated open heart surgeries. Products in the global antithrombin market are absolutely essential for the long term treatment of thrombotic diseases. This is positively influencing the sales as well as production of the antithrombin drugs in the global antithrombin market. Furthermore, rising usage of rapid diagnostic tests that use antithrombin are also triggering an increased need for solutions and protein molecules in the global antithrombin market.
Download Sample @ https://qyresearchmedical.com/sample/111584
However, rising utilization of biologics as well as high cost associated with antithrombin are two of the key challenges for the growth of the global antithrombin market in coming years. Solutions in the global antithrombin market replicate the antithrombin protein created by the liver in human body. This protein aids in reducing the clotting of the blood by inactivating the thrombin compounds. Products in the global antithrombin market are used in various healthcare scenarios such as cardiac surgeries as well as in antithrombin deficiency disorders. Rising disposable incomes in emerging economies and adoption of new treatment procedures are also some of the major drivers for the global antithrombin market.
Furthermore, increase in the occurrence of venous thromboembolism or VTE is various western economies is fueling the demand in the global antithrombin market. Moreover, rising awareness pertaining to thrombotic diseases and its ill effects on human body such as liver failure, severe burns, and nephrotic syndrome, is also favoring the adoption of the remedies and solutions offered by the players and manufacturers in the global antithrombin market. Furthermore, increase in the usage of solutions in the global antithrombin market for various therapeutic process in the healthcare sector is also anticipated to positively impact the demand dynamics of the global antithrombin market in the next few years.
The global antithrombin treatment market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of hereditary antithrombin deficiency to escalate the growth of global antithrombin treatment market. Moreover, adoption of new therapeutics is projected to drive the global antithrombin treatment market during the forecast period
Key Drivers of Global Antithrombin Treatment Market
The acceptance of antithrombin in several medical conditions over conventional once is contribute to driving the demand for products and thereby drive the global antithrombin market.
Antithrombin is approved by FDA as anticoagulant and indicated in venous thromboembolic events in hereditary antithrombin deficient patients. Antithrombin also used in treatment of disseminated intravascular coagulation syndrome (DIC) and extracorporeal membrane oxygenation (ECMO), etc. Thus, gradual increase in prevalence of hereditary antithrombin deficiency leading to increase in the demand for the products and thereby drive the growth of market.
Key players are investing in research and development in order to develop new therapeutics to address the unmet needs. This in turn to drive the growth of the global antithrombin treatment market. For instance, China Biologic Products Holdings, Inc. integrated plasma-based biopharmaceutical company in China develop Human Antithrombin III for treatment of hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and thromboembolism is in clinical trial phase III.
Technological Advancements Propel Global Antithrombin Treatment Market Growth
Technological advancements have helped bring down the total costs involved in production of therapeutic proteins. This has encouraged suppliers and manufacturers to seek newer avenues of therapeutic protein manufacturing and also to deal with longer and complex chains of peptides. Technological advancements in antithrombin is likely to boost the growth of the market in the near future
Pricing Pressure to Hamper Global Antithrombin Treatment Market
Pricing is one of the concern over substitute and conventional anticoagulant therapy which could hamper growth of global antithrombin market. In many regions like Asia Pacific and Europe price concern hampers adoption of antithrombin therapy as there also pricing pressures, as antithrombin is seen as an expensive treatment with few returns.
Global Antithrombin Treatment Market: Competitive Landscape
This report profiles major players in the global antithrombin treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global antithrombin treatment market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global antithrombin treatment market are rEVO Biologics, Inc., Grifols, Shire plc., CSL Limited, Kedrion S.p.A, Octapharma AG, Dem ilac Inc., Lee Bisolutions, Diapharma, Scripps Laboratories, Inc. and Other Prominent Companies
Global Antithrombin Treatment Market: Key Developments
Key players in the global antithrombin treatment market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global antithrombin treatment market. A few expansion strategies adopted by players operating in the global antithrombin treatment market are:
In September 2017, Kyowa Hakko Kirin Co., Ltd. received approval for additional formulation, ACOALAN injection 1800 IU
In August 2017, CSL Limited completed transaction to acquire a majority stake in China-based plasma fractionator, Wuhan Zhong Yuan Rui De Biological Products Co. Ltd.
In July 2017, CSL Ltd. announced launch of Haegarda (subcutaneous C1-INH, CSL830) in the U.S. approved for the treatment of hereditary angioedema (HAE) in patients
In January 2016, Octapharma announced launch of Nuwiq used in hemophilia patients to control bleeding, perioperative (surgical) management, and routine prophylaxis, in adults and children with hemophilia A
The report on the global antithrombin treatment market discussed individual strategies, followed by company profiles of manufacturers of antithrombin products. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global antithrombin treatment market.
Key Questions Answered in Global Antithrombin Treatment Market Report
- What is the scope of growth for product companies in the global antithrombin treatment market?
- What will be the Y-o-Y growth of the global antithrombin treatment market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global antithrombin treatment market?
- Will North America continue to be the most profitable market for antithrombin treatment providers?
- Which factors are anticipated to hamper the growth of the global antithrombin treatment market during the forecast period?
- Which are the leading companies in the global antithrombin treatment market?
Global Antithrombin Treatment Market – Segmentation
Application
- Therapeutic
- Research
- Diagnostics
Source
- Human
- Goat Milk
- Others (Bovine, etc.)
Dosage Form
- Lyophilized
- Liquid
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111584/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/